| Class / Patent application number | Description | Number of patent applications / Date published |
|---|
| 800010000 | Cancer | 56 |
| 20080222741 | Expression Profile Of Prostate Cancer - The present invention relates to compositions and methods for cancer diagnostics, including but not limited to, cancer markers. In particular, the present invention provides gene expression profiles associated with prostate cancers. Genes identified as cancer markers using the methods of the present invention find use in the diagnosis and characterization of prostate cancer. In addition, the genes provide targets for cancer drug screens and therapeutic applications. | 09-11-2008 |
| 20090049561 | NON-HUMAN ANIMAL EXHIBITING BONE METASTASIS OF TUMOR CELLS - The present invention provides a non-human bone metastasis model animal in which tumor cells capable of inducing bone metastasis by peripheral administration have been introduced, and a method for producing the animal. The bone metastasis model animal in the present invention may be useful for understanding the biology of bone metastasis and developing novel therapeutic strategies for lung cancer patient with multi-organ metastases, including bone metastasis | 02-19-2009 |
| 20090070889 | MOUSE MODEL COMPRISING AN ENGRAFTED HUMAN SKIN HAVING HYPERSENSITIVITY TO UV-LIGHT - The present invention relates to a humanized, non-human mammal model, preferably a humanized mouse model, with an engrafted portion of human skin having hyper-patient sensitivity to ultra violet (UV) light, and a method for preparing such non-human mammal model and its use for studying acute and long term effects on human skin by exposure to UV light and for testing topically or systematically applied or administered substances for their capability to prevent, repair and/or cure damages of such exposed human skin. This mouse model comprises an engrafted portion of human skin based on skin cells of a human Xeroderma pigmentosum (XP) or Gorlin's Syndrome (GS) patient. XP and GS are rare human autosomal disorders characterized clinically by hypersensitivity to UV light, especially to UVB rays, and high predisposition for developing skin cancers on sunlight exposed skin areas. | 03-12-2009 |
| 20090083869 | METHODS AND COMPOSITIONS FOR IDENTIFYING AGENTS THAT INHIBIT AN NS4B-MEDIATED NEOPLASTIC CELLULAR PHENOTYPE OF HCV INFECTED CELLS - The disclosure provides methods and compositions for identifying agents that inhibit a neoplastic cellular phenotype mediated by the NS4B protein nucleotide binding motif (NBM) of hepatitis C virus (HCV). In general, the methods involve contacting a candidate agent with a mammalian cell expressing an NS4B NBM polypeptide of an HCV virus, wherein expression of the NS4B NBM polypeptide in the absence of candidate agent promotes a neoplastic cellular phenotype, and detecting the presence or absence of an effect of said candidate agent on NS4B-mediated promotion of a neoplastic cellular phenotype. The disclosed methods and compositions find use in a variety of therapeutic and screening applications. | 03-26-2009 |
| 20090293138 | ANIMAL MODELS CARRYING TUMORS EXPRESSING HUMAN PROSTATE CANCER-SPECIFIC ANTIGEN AND METHOD FOR ANALYZING PREVENTION AND TREATMENT EFFICACY OF DENDRITIC CELLS-DERIVED IMMUNOTHERAPEUTICS - A method for analyzing the prevention and treatment efficacy of a dendritic cell-derived immunotherapeutic for prostate cancer using an animal model carrying tumors expressing a human prostate cancer-specific antigen includes either administering to a normal non-human animal dendritic cells to be analyzed, or administering to a normal non-human animal a cancer cell line expressing the human prostate cancer-specific antigen to induce cancer in the normal non-human animal; administering to the animal the cancer cell line expressing the human prostate cancer-specific antigen to induce cancer in the animal when the dendritic cell administering step was performed, or administering to the animal with cancer dendritic cells to be analyzed when the human prostate cancer-specific antigen expressing cell line administering step was performed; and determining the prevention and treatment efficacy of the dendritic cells as immunotherapeutics for prostate cancer by measuring the formation or growth of cancer cells originated from the cancer cell line in the animal. | 11-26-2009 |
| 20090300779 | Cancer selective auxotrophs - Bacteria that are auxotrophic for at least two amino acids found in at least one tumor are effective anti tumor treatments, labeling agents, and vaccines against infection. Improved antitumor effects can also be provided such strains by passage through an appropriate tumor model. | 12-03-2009 |
| 20100017900 | Prostate Epithelial Androgen Receptor Suppresses Prostate Growth and Tumor Invasion - Described herein is the generation of the first conditional knockout AR (pes-ARKO) mice that lack AR only in prostate epithelia. Additionally demonstrated herein, through AR gain- and loss-of-function experiments, are the novel growth and differentiation roles of epithelial AR within the normal and cancerous prostate cells. | 01-21-2010 |
| 20100024049 | Digestive System Cancer Stem Cells and Tests and Uses Therefor - The CD133 marker has been found to be diagnostic of tumourigenic digestive system cancer, particularly malignant colorectal cancers. Tests to show such cells and uses for such cells are disclosed. | 01-28-2010 |
| 20100037328 | CD20-NEGATIVELY CONVERTED B CELL MALIGNANT LYMPHOCYTE CELL LINE AND UTILIZATION OF THE SAME - It is intended to provide a tool, a procedure and so on which are useful in developing a therapeutic strategy efficacious in inhibiting or overcoming the resistance against a CD20-directed molecular-targeted drug. Thus, a CD20-negatively converted B-cell malignant lymphocyte cell line is provided. Also, a model animal indicating the pathological conditions of CD20-negatively converted B-cell malignant lymphocyte is provided. Further, a method of screening a substance, which is efficacious against CD20-positive B-cell malignant lymphocyte or CD20-negatively converted B cell malignant lymphocyte, is provided. Furthermore, a drug against CD20-positive B-cell malignant lymphocyte or CD20-negatively converted B-cell malignant lymphocyte, which is characterized by being used together with a CD20-directed molecular-targeted drug, is provided. In one embodiment, a DNA methylase inhibitor or a histone deacetylase inhibitor is employed as the active ingredient. | 02-11-2010 |
| 20100071081 | METHOD FOR STIMULATING DENDRITIC CELLS AND CELL PRODUCT THUS OBTAINED FOR THE AUTOLOGOUS IMMUNOTHERAPY OF SOLID HUMAN TUMOURS - In the ex vivo stimulation method of dendritic cells, the stimulation occurs with the lysate of tumour spheres (TS) of the solid tumours. | 03-18-2010 |
| 20100083391 | Cancer Compositions, Animal Models, and Methods of Use Thereof - The construction of animal models of cancer and methods of using the models to screen potential cancer therapeutics are described. | 04-01-2010 |
| 20100162419 | TUMOR-INITIATING CELLS AND METHODS OF USE - Provided herein are an isolated or enriched population of tumor initiating cells derived from normal cells, cells susceptible to neoplasia, or neoplastic cells. Methods of use of the cells for screening for anti-hyperproliferative agents, and use of the cells for animal models of hyperproliferative disorders including metastatic cancer, diagnostic methods, and therapeutic methods are provided. | 06-24-2010 |
| 20100162420 | GASTRIC CARCINOMA GENE ZNF312B, A PROTEIN TRANSLATED FROM THE GENE, AND A DIAGNOSTIC KIT AND A SCREENING METHOD FOR ANTICANCER AGENTS USING THE SAME - The present invention relates to a diagnostic marker containing ZNF312b gene and the fragment thereof, a diagnostic method for stomach cancer and a screening method for stomach cancer inducers or inhibitors using the same. ZNF312b gene expression is specifically increased in stomach cancer. And the over-expression or the under-expression of the gene affects activation or inhibition of cell proliferation and tumor formation of a stomach cancer cell line and cell proliferation signal transduction system as well to induce stomach cancer at last. Therefore, ZNF312b marker gene can be effectively used for diagnosis of stomach cancer, construction of a stomach cancer animal model, prevention and treatment of stomach cancer and development of a stomach cancer specific anticancer agent. | 06-24-2010 |
| 20100169990 | COMPOSITIONS AND METHODS FOR TREATING AND DIAGNOSING CANCER - The present invention relates to compositions and methods for characterizing, treating and diagnosing cancer. In particular, the present invention provides a cancer stem cell profile, as well as novel stem cell cancer markers useful for the diagnosis, characterization, prognosis and treatment of cancer and in particular the targeting of solid tumor stem cells. | 07-01-2010 |
| 20100223680 | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation - The present invention provides tumor cell preparations for use as models of the EMT process for use in the identification of anti-cancer agents, wherein said tumor cell preparations comprise cells of the epithelial tumor cell line CFPAC-1, which are stimulated by receptor ligands to induce EMT, or which have been engineered to inducibly express a protein that stimulates EMT. The present invention also provides methods of identifying potential anti-cancer agents by using such tumor cell preparations to identify agents that inhibit EMT, stimulate MET, or inhibit the growth of mesenchymal-like cells. Such agents should be particularly useful when used in conjunction with other anti-cancer drugs such as EGFR and IGF-1R kinase inhibitors, which appear to be less effective at inhibiting tumor cells that have undergone an EMT. | 09-02-2010 |
| 20100235932 | ANIMAL MODELS CARRYING TUMORS EXPRESSING HUMAN LIVER CANCER-SPECIFIC ANTIGEN AND METHOD FOR ANALYZING PREVENTION AND TREATMENT EFFICACY OF DENDRITIC CELLS-DERIVED IMMUNOTHERAPEUTICS USING THE ABOVE - The present invention relates to a method for analyzing the prevention and treatment efficacy of a dendritic cell-derived immunotherapeutic for liver cancer using an animal model carrying tumors expressing a human liver cancer-specific antigen, which comprises the steps of: (a) (a1) administering to a normal animal other than human dendritic cells to be analyzed, or (a1) administering to a normal animal other than human a cancer cell line expressing the human liver cancer-specific antigen to induce cancer in the normal animal; (b) (b1) administering to the animal the cancer cell line expressing the human liver cancer-specific antigen to induce cancer in the animal when the step (a1) is performed in the step (a), or (b1) administering to the animal with cancer dendritic cells to be analyzed when the step (a1) is performed in the step (a); and (c) determining the prevention and treatment efficacy of the dendritic cells as immunotherapeutics for liver cancer by measuring the formation or growth of cancer cells originated from the cancer cell line in the animal. | 09-16-2010 |
| 20100287631 | WNT PATHWAY MUTATIONS IN CANCER STEM CELLS - Cancer specific splicing events in the Wnt/β-catenin signaling pathway are associated with progression of myelogenous leukemia. Misspliced genes of interest include GSK3β. In some embodiments of the invention, polynucleotides are provided that correspond to misspliced GSK3β transcripts associated with cancer. Such transcripts are characterized by a deletion of exon (8), and particularly in exon (8) and (9). Detection of such transcripts in cells is indicative of the presence of leukemia, and particularly of the presence of leukemia stem cells. In other embodiments, polypeptides are provided that are encoded by misspliced GSK3β transcripts associated with cancer. Such polypeptides are useful as diagnostic markers for cancer, and as a target for screening of therapeutic agents. Animal models comprising a human LSC having a misspliced GSK3b transcript provide a useful model for leukemia, for drug/gene screening in the prevention and treatment of leukemia in humans, etc. | 11-11-2010 |
| 20110004950 | Method for Manufacturing Animal Model for Researching Pulmonary Tumor and Use Thereof - The present invention is a method for manufacturing an animal model for researching a pulmonary tumor and a use thereof. A transgenic non-human animal of the present invention is prepared by embryonic gene microinjection and possesses a tissue-specific expression of vascular endothelial growth factor A | 01-06-2011 |
| 20110030074 | COMPOSITIONS AND METHODS FOR CANCER GENE DISCOVERY - The present invention features transgenic non-human mammalian animals being genetically modified to develop cancer. The invention also relates to methods for identifying genes or genetic elements that are potentially related to human cancers using an chromosomally unstable animal model. Information on such genetic alterations can be used to predict cancer therapeutic outcomes and to stratify patient populations to maximize therapeutic efficacy. | 02-03-2011 |
| 20110061116 | Animal Model of Synovial Sarcoma - Synovial sarcoma is an aggressive soft-tissue malignancy. Disclosed herein is an animal model of synovial sarcoma wherein one or more myogenic cells of the animal express recombinant SYT-SSX fusion polypeptide. Using this model, myoblasts were identified as a source of synovial sarcoma. Remarkably, within the skeletal muscle lineage, while expression of the oncoprotein in immature myoblasts leads to induction of synovial sarcoma with 100% penetrance, its expression in more differentiated cells induces myopathy without tumor induction. In addition, early widespread expression of the disclosed fusion protein disrupts normal embryogenesis, causing lethality. | 03-10-2011 |
| 20110119776 | METHODS OF DIAGNOSING AND PROGNOSING LUNG CANCER - The present invention provides methods of detecting cancer using biomarkers. | 05-19-2011 |
| 20110179505 | RODENT CANCER MODEL FOR HUMAN FGFR4 ARG388 POLYMORPHISM - The present invention provides a rodent animal for studying the molecular mechanisms and physiological processes associated with uncontrolled cell growth, e.g. cancer, and with a modified FGFR4. | 07-21-2011 |
| 20110283372 | COMPOSITIONS USEFUL FOR CANCER DETECTION AND TREATMENT, A CANCER STEM CELL MODEL, AND METHODS OF PRODUCTION AND USE THEREOF - DCAMKL-1 has been identified as a biomarker for stem cells, as well as cancer stem cells. Methods of detecting the presence of at least one stem cell, methods of isolating stem cells, and methods of inhibiting growth of cancer cells utilizing DCAMKL-1 are disclosed herein. | 11-17-2011 |
| 20120117672 | ISOLATION AND GROWTH OF STEM CELLS FROM HEMANGIOMAS - The present invention describes stem cells and progenitor cells derived from hemangiomas, including testing of angiogenic inhibitors using these cells. The invention as described is useful in providing a process to culture and propagate hemangioma stem cells and generate xenograft models to develop treatments for infantile hemangiomas and other types of vascular lesions. | 05-10-2012 |
| 20120144510 | TREATMENT OF ASTROCYTES-TUMOR CELLS INHIBITORS OF ENDOTHELIN RECEPTORS - The disclosure relates to an endothelin receptor antagonist for use in the prevention or treatment of brain metastases in combination with a cytotoxic chemotherapy agent, radiotherapy or both. The endothelin receptor antagonist may for example be bosentan, macitentan or a mixture of bosentan and macitentan. | 06-07-2012 |
| 20120174241 | Mouse model for diagnosis of T cell acute lymphoblastic leukemia and for screening of therapeutic agents, and methods of use therefor - The invention provides mutant or transgenic animals and cells derived from the mutant or transgenic animals, and particularly a transgenic mouse, that is useful, among other things, for the study, prognosis and diagnosis of hematological malignancies, including T-cell acute lymphoblastic leukemia (T-ALL). Methods are provided for using the mouse model or mutant animal cells to assist in the discovery and identification of genes that may promote lymphomagenesis, to prognose and diagnose disease, and to screen for potential therapeutic agents or drugs. | 07-05-2012 |
| 20120222142 | GUT FLORA-DERIVED EXTRACELLULAR VESICLES, AND METHOD FOR SEARCHING FOR A DISEASE MODEL, VACCINE, AND CANDIDATE DRUG AND FOR DIAGNOSIS USING THE SAME - The present application relates to a composition including gut flora-derived extracellular vesicles, and to an animal disease model using same. In addition, the present application relates to a method for using the gut flora-derived extracellular vesicles to efficiently search for a candidate drug which may prevent or treat diseases that occur due to gut flora-derived extracellular vesicles, and to a vaccine which can efficiently prevent or treat infections caused by gut flora or diseases that occur due to gut flora-derived extracellular vesicles. Further, the development of diagnostic technology to discover, using the gut flora-derived extracellular vesicles of the present application, the etiology of diseases that occur due to gut flora-derived extracellular vesicles, can be achieved. | 08-30-2012 |
| 20120272346 | IDENTIFICATION OF RNAI TARGETS AND USE OF RNAI FOR RATIONAL THERAPY OF CHEMOTHERAPY-RESISTANT LEUKEMIA AND OTHER CANCERS - Provided is a mosaic mouse model for use in determining the potency of an shRNA in vivo for reducing survival of cancer cells of chemotherapy-resistant leukemia. The syngeneic mouse recipient is transplanted with tet-on competent leukemia cells carrying a bicistronic nucleic acid construct comprising a promoter operably linked to a fusion gene associated with chemotherapy-resistant leukemia, and a sequence encoding a reverse tet-transactivator protein, such that both coding sequences are co-expressed from the promoter. Also provided are methods of treating soft tissue cancers. | 10-25-2012 |
| 20120272347 | CHITOSAN-ALGINATE SCAFFOLD CELL CULTURE SYSTEM AND RELATED METHODS - Methods for culturing cancer cells in vitro using a three-dimensional scaffold, scaffolds that include the cultured cancer cells, and methods for using the cultured cancer cells and the scaffolds that include the cultured cancer cells in anticancer therapeutic drug development. | 10-25-2012 |
| 20120304319 | TOX3 AS A BIOMARKER FOR BREAST CANCER - The invention provides compositions and methods for detecting and/or modulating TOX3 gene expression and/or biological activity. Such compositions and methods find utility in the detection and/or treatment of certain subsets of cancers, e.g. breast cancer. In particular, the inventive compositions and methods are drawn to production and use of anti-TOX3 antibodies and TOX3 nucleic acids for both detection and modulation of TOX3. The invention also provides for pharmaceutical compositions and methods for the modulation of TOX3 in a subject in need thereof. Further aspects of the invention relate to transgenic mice that either over-express or inducibly express TOX3. | 11-29-2012 |
| 20130019327 | METHOD FOR SEARCHING AND SCREENING FOR TARGET OF ANTI-CANCER AGENT USING NON-HUMAN ANIMAL MODEL HAVING NOG ESTABLISHED CANCER CELL LINE TRANSPLANTED THEREINAANM Suzuki; MasamiAACI ShizuokaAACO JPAAGP Suzuki; Masami Shizuoka JPAANM Matsubara; KoichiAACI HeliosAACO SGAAGP Matsubara; Koichi Helios SGAANM Kato; AtsuhikoAACI ShizuokaAACO JPAAGP Kato; Atsuhiko Shizuoka JPAANM Kato; ChieAACI ShizuokaAACO JPAAGP Kato; Chie Shizuoka JPAANM Kobayashi; ShintaAACI HeliosAACO SGAAGP Kobayashi; Shinta Helios SGAANM Chen; Yu JauAACI HeliosAACO SGAAGP Chen; Yu Jau Helios SGAANM Yamazaki; MasakiAACI HeliosAACO SGAAGP Yamazaki; Masaki Helios SG - An objective of the present invention is to provide non-human animal models of cancer pathology, which mimic the hierarchical organization, cancer progression process, or biological property of human cancer tissues, and uses thereof. To achieve the objective described above, first, the present inventors transplanted cells of NOG-established cancer lines into NOG mice and morphologically observed the resulting tissue organization. As a result, the non-human animal models were demonstrated to exhibit pathologies (the hierarchical organization, cancer progression process, or biological properties of the cancer cells) similar to that of human cancer. Specifically, the present inventors succeeded in preparing non-human animal models exhibiting pathologies more similar to a human cancer, and cell culture systems using NOG-established cancer cell lines where the in vitro cell morphology is more similar to that of human cancer. | 01-17-2013 |
| 20130042333 | MARKERS FOR CANCER PROGNOSIS AND THERAPY AND METHODS OF USE - The invention relates generally to the field of cancer prognosis and treatment. More particularly, the present invention relates to methods and compositions that utilize a particular panel of gene products (“biomarkers”) and their differential expression patterns (“expression signatures”), wherein the expression patterns correlate with responsiveness, or lack thereof, to chemotherapy treatment. The invention is based on the identification of a specific set of biomarkers that are differentially expressed in chemotherapy-treated tumors and which are useful in predicting the likelihood of a therapeutic response, including residual disease persistence and subsequent tumor recurrence in cancer patients receiving chemotherapy. The gene panel is also useful in designing specific adjuvant modalities with improved therapeutic efficiency. Also disclosed are methods for characterizing tumors according to expression of the biomarkers described herein. | 02-14-2013 |
| 20130061340 | Identification and Enrichment of Cell Subpopulations - Markers useful for the identification, characterization and, optionally, the enrichment or isolation of tumorigenic cells or cell subpopulations are disclosed. | 03-07-2013 |
| 20130145486 | METHOD FOR PRODUCING TUMOR CELL - The object of the invention is to provide a method for producing tumor cells by carrying out gene transfer into cells derived from normal cells. The invention provides a method for producing tumor cells by transferring cancer-associated genes into immortalized small airway epithelial cells. | 06-06-2013 |
| 20130167255 | SCREENING METHOD FOR ANTICANCER DRUGS - Use of an animal model of spontaneous metastasis bearing a tumor derived from a cell line RM72 (Accession No. NITE BP-1110) allows simultaneous evaluation of tumorigenesis and spontaneous cancer metastasis. Use of a screening method using the animal model of spontaneous metastasis allows the obtainment of a substance having an anticancer activity and/or an anti-metastatic activity. Use of another screening method for selecting a substance that increases the expression of RECK in a cancer cell allows the obtainment of a substance that can serve as an active ingredient in an anticancer drug. | 06-27-2013 |
| 20130198876 | INDUCED MALIGNANT STEM CELLS OR PRE-INDUCTION CANCER STEM CELLS CAPABLE OF SELFREPLICATION OUTSIDE OF AN ORGANISM, PRODUCTION METHOD FOR SAME, AND PRACTICAL APPLICATION FOR SAME - The present invention provides an induced cancer cell capable of self-replication in vitro which is useful in cancer therapy research and the research for cancer-related drug discovery, processes for production thereof, cancer cells induced by the malignant cells, and applications of these cells. | 08-01-2013 |
| 20130212721 | REAGENT FOR TUMOR TESTING AND PHARMACEUTICAL COMPOSITION FOR TUMOR PREVENTION - The present invention aims to provide a novel reagent for tumor testing and a novel pharmaceutical composition for tumor prevention. | 08-15-2013 |
| 20130219531 | IMMORTALIZED HUMAN PROSTATE CELL LINES - Immortalized human cell lines derived from prostate cells are disclosed. Immortalized cells derived from a human epithelial prostate tissue cancer tumor are provided, as well as immortalized cells derived from healthy human epithelial prostate tissue from the same patient. Methods for utilizing such immortalized cell lines for researching, screening, and evaluating antimalignancy therapies and drug candidates are also disclosed. | 08-22-2013 |
| 20130239239 | LMCD1 CANCER MARKERS AND METHODS FOR THEIR USE - The present invention provides LMCD1 cancer markers, and methods, compositions, and kits for their use. The invention also provides expression vectors, host cells, and transgenic animals comprising one or more LMCD1 mutations, and methods for their use in characterizing, diagnosing, and treating cancers, and for identifying potential therapeutics. The invention also provides cancer therapeutics. | 09-12-2013 |
| 20130263296 | CANCER IMAGING WITH THERAPY: THERANOSTICS - Genetic constructs comprising reporter genes operably linked to cancer specific or cancer selective promoters (such as the progression elevated gene-3 (PEG-3) promoter) are provided, as are methods for their use in cancer imaging, cancer treatment, and combined imaging and treatment protocols. Transgenic animals in which a reporter gene is linked to a cancer specific or cancer selective promoter, and which may be further genetically engineered, bred or selected to have a predisposition to develop cancer, are also provided. | 10-03-2013 |
| 20130263297 | METHODS OF TREATING CANCER - The present invention relates to metastases. More specifically, the invention relates to compositions and methods for the inhibition of metastases of cancer cells, such as prostate cancer cells, to bones and soft tissue. The present invention also relates to the treatment of cancer, including but not limited to prostate cancer. Also provided are animal models for studying cancer metastasis; particularly, prostate cancer metastasis. Further provided are compositions, processes and systems to prognosticate cancer. | 10-03-2013 |
| 20140026234 | BIOMARKERS AND THEIR USES IN CANCER DETECTION AND THERAPY - Presented herein are novel protein biomarkers related to cancers with stromal components. These newly identified biomarkers create the basis for multiple (single) assays using traditional bioassay technologies and when used in combination yield exceptional clinical sensitivity and specificity in the determination of diagnosis and/or prognosis of cancer. A new genetic model able to identify potential genetic suppressors and/or potential therapeutic agents for treating stromal cancers is also described. Means and methods for evaluating data generated using multiple biomarkers in order to validate findings and further the use of the biomarkers and the genetic model system in clinical, diagnostic and therapeutic uses is also included. | 01-23-2014 |
| 20140109245 | PROSTATE CANCER CELL LINES, GENE SIGNATURES AND USES THEREOF - The present disclosure, in part, is directed to a mammalian prostate cancer cell line comprising at least one or a set of primary mammalian epithelial cells which have been infected with a retroviral vector carrying an oncogene selected from the group consisting of c-Myc, Ha-Ras, NeuT, c-Src and combinations thereof and in which said gene is expressed. Applications of the pro-state cell lines, including immune competent animal models of prostate cancer, a method for the in vitro production of immortalized primary mammalian epithelial cells, a method of determining whether a human subject having prostate cancer is suffering from or at risk for developing metastasis, a method of preventing cancer or inhibiting metastasis of cancer susceptible to treatment in a subject at risk for developing cancer or metastasis of cancer, and method of identifying a candidate compound that selectively interferes with proliferation or viability of a cancer cell that has elevated levels of CCR5 and/or of at least one of its ligands. | 04-17-2014 |
| 20140109246 | METHODS OF GENERATING XENOCHIMAERIC MICE WITH TUMOR AND HEMATOPOIETIC SYSTEM FROM THE SAME HETEROLOGOUS SPECIES - The present invention provides methods for the generation of xenochimaeric animals; for example, xenochimaeric mice, comprising bone marrow progenitor cells and tumors from a heterologous animal. In some aspects, the invention provides xenochimaeric mice bearing humanized bone marrow and human tumors. Such animals are a model system for the study of human tumor stroma, for drug discovery, and for the treatment of human cancers. | 04-17-2014 |
| 20140137274 | INDUCED MALIGNANT STEM CELLS | 05-15-2014 |
| 20140157443 | METHODS AND COMPOSITIONS FOR DETECTING AND MODULATING A NOVEL MTOR COMPLEX - Provided herein is a novel mTOR-comprising complex, mT-ORC3, which comprises mTOR and the Ets transcription factor TEL2. Specific mTORC3 binding agents and modulating agents are provided, along with kits and methods for the detection of mTORC3. Methods of modulating the activity of mTORC3 or modulating cell growth and/or survival are also provided. Further provided are methods for screening for mTORC3 binding agents and for mTORC3 modulating agents. Various methods of diagnosis and treatment are further provided. | 06-05-2014 |
| 20140157444 | WDR13 AS A NOVEL BIOMARKER USEFUL FOR TREATING DIABETES AND CANCER - WD-repeat proteins are very diverse, yet these are structurally related proteins that participate in a wide range of cellular functions. WDR13, a member of this family, is conserved from fishes to humans and localizes into the nucleus. To understand the in vivo function(s) of Wdr13 gene, we have created and characterized a mutant mouse strain lacking this gene. The mutant mice had higher serum insulin levels and increased pancreatic islet mass as a result of the enhanced beta cell proliferation. While a known cell cycle inhibitor, p21, was down regulated in the mutant islets overexpression of WDR13 in the pancreatic MIN6 cell line resulted in upregulation of p21, accompanied by retardation of cell proliferation. We suggest that WDR13 is a novel negative regulator of the pancreatic beta cell proliferation. Co-immunoprecipitation experiments showed that this protein interacts with estrogen receptors and various HDACs. We provide evidence to show that WDR13 can regulate estrogen receptors-mediated transcription both in HDAC-dependent and HDAC-independent manner. Given the higher insulin levels, better glucose clearance and the lack of insulin resistance in WDR13 deficient mice, we propose that this protein may be a potential candidate drug target for ameliorating impaired glucose metabolism in diabetes. | 06-05-2014 |
| 20140215644 | SOLUBLE PROTEIN CD5 OR CD6 FOR THE TREATMENT OF CANCER OR TUMOR OR FOR USE AS AN ADJUVANT - The present invention discloses soluble isoforms of CD5 and CD6, which are scavenger-like lymphocyte receptors, for use in the prophylaxis or therapy of disorders or in therapeutic interventions, which would benefit from an exacerbated immune response to either endogenous or exogenous antigens, resulting from a decrease in lymphocyte subpopulations with regulatory functions and/or increase in lymphocyte subpopulations with effector functions. Special disorders are cell growth disorders, and chronic infections of bacterial, viral, fungal or parasitic origin. The invention also provides animal models for the study and the prophylaxis/treatment of autoimmune diseases, cancer, and chronic infections. | 07-31-2014 |
| 20140298498 | INHIBITION OF ONCOGENIC KRAS-INDUCED GM-CSF PRODUCTION AND FUNCTION - The present invention is directed to methods of inhibiting tumor growth in a subject. The present invention is further directed to methods of diagnosing cancer in a subject and identifying a suitable course of treatment for the subject based on the diagnosis. The present invention is also directed to an orthotopic animal model of pancreatic cancer. | 10-02-2014 |
| 20150135341 | TUMOR-INITIATING CELLS AND METHODS OF USE - Provided herein are an isolated or enriched population of tumor initiating cells derived from normal cells, cells susceptible to neoplasia, or neoplastic cells. Methods of use of the cells for screening for anti-hyperproliferative agents, and use of the cells for animal models of hyperproliferative disorders including metastatic cancer, diagnostic methods, and therapeutic methods are provided. | 05-14-2015 |
| 20150135342 | CELL LINE OF RENAL SARCOMATOID CARCINOMA IN PERSONS OF HAN NATIONALITY AND PREPARATION METHOD THEREOF - Provided is a renal sarcomatoid cell line RCC09HYF, of which the deposit No. is CCTCC C201130, and the preparation method of the renal sarcomatoid cell line. The renal sarcomatoid cell line RCC09HYF can grow for a long period and be steadily passaged in vitro. By tumorigenic experiments using in-situ animal models in vitro it has been found that: the tumorigenesis is relatively fast inside animals and 3-4 weeks after tumor inoculation, the transplanted tumors fill the whole abdominal cavity, and dyscrasia appears in above 50% of nude mice; moreover, lung metastasis is present in a few individuals. The renal sarcomatoid cell line RCC09HYF can provide an effective and steady cell model for further study of the genesis and metastasis mechanism of renal sarcomatoid carcinoma in persons of Han nationality and for clinical prediction, diagnosis and treatment. | 05-14-2015 |
| 20160007578 | Animal Models of Cancer | 01-14-2016 |
| 20160066551 | NON HUMAN ANIMAL MODEL FOR ULCERATIVE COLITIS AND ITS MAIN COMPLICATIONS - The present invention relates to a non human model animal for ulcerative colitis and its main complications such as primary sclerosing cholangitis and colorectal cancer. More particularly, the present invention relates to a transgenic non human animal model for ulcerative colitis and its main complications such as primary sclerosing cholangitis, and colorectal cancer comprising a targeted disruption in the IL10 and NOX1 genes so that IL10 and NOX1 are not expressed in said animal. | 03-10-2016 |
| 20160074391 | MEANS AND METHODS FOR TREATING CANCER - The present invention relates to a pharmaceutical composition comprising a compound of formula (I) | 03-17-2016 |
| 20160157470 | NON-HUMAN ANIMALS HAVING A HUMANIZED CLUSTER OF DIFFERENTIATION 47 GENE - Non-human animals, and methods and compositions for making and using the same, are provided, wherein said non-human animals comprise a humanization of an endogenous cluster of differentiation (CD) gene, in particular a humanization of a CD47 gene. Said non-human animals may be described, in some embodiments, as having a genetic modification to an endogenous CD47 gene so that said non-human animals express a CD47 polypeptide that includes a human portion and a non-human portion (e.g., a murine portion). | 06-09-2016 |
| 20190145977 | METHODS OF DIAGNOSING AND PROGNOSING LUNG CANCER | 05-16-2019 |
